Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Revenue (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Revenue for 11 consecutive years, with -$1.4 million as the latest value for Q4 2025.

  • Quarterly Revenue fell 91.04% to -$1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$52000.0 through Dec 2025, down 100.14% year-over-year, with the annual reading at $400000.0 for FY2025, 98.97% down from the prior year.
  • Revenue for Q4 2025 was -$1.4 million at Cartesian Therapeutics, down from $298000.0 in the prior quarter.
  • The five-year high for Revenue was $39.3 million in Q2 2022, with the low at -$1.4 million in Q4 2025.
  • Average Revenue over 5 years is $14.5 million, with a median of $9.7 million recorded in 2021.
  • Peak annual rise in Revenue hit 533.85% in 2024, while the deepest fall reached 109.18% in 2024.
  • Over 5 years, Revenue stood at $29.9 million in 2021, then crashed by 43.9% to $16.8 million in 2022, then tumbled by 50.78% to $8.3 million in 2023, then plummeted by 109.18% to -$759000.0 in 2024, then crashed by 91.04% to -$1.4 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at -$1.4 million, $298000.0, and $1.1 million for Q4 2025, Q2 2025, and Q1 2025 respectively.